Quince Therapeutics Amends 8-K, Confirms QNCX Common Stock Listing
Ticker: QNCX · Form: 8-K/A · Filed: Jan 5, 2024 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K/A |
| Filed Date | Jan 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: amendment, corporate-governance, stock-listing
TL;DR
**Quince Therapeutics (QNCX) filed an 8-K/A clarifying its common stock listing details.**
AI Summary
Quince Therapeutics, Inc. filed an 8-K/A on January 5, 2024, amending its previous 8-K from October 20, 2023. This amendment clarifies that its Common Stock, with a par value of $0.001 per share, is registered under the trading symbol QNCX on the Nasdaq Stock Market. This matters to investors because it confirms the specific details of the company's publicly traded shares, ensuring transparency and proper identification for trading purposes.
Why It Matters
This filing provides updated and corrected information regarding Quince Therapeutics' publicly traded common stock, ensuring investors have accurate details for trading and regulatory compliance.
Risk Assessment
Risk Level: low — This is an administrative amendment providing clarification, not indicating any new operational or financial risks.
Analyst Insight
Investors should note this administrative update confirms the correct trading symbol and exchange for Quince Therapeutics' common stock, ensuring accurate record-keeping and trading information.
Key Numbers
- $0.001 — Par Value per Share (The stated par value for Quince Therapeutics' Common Stock.)
Key Players & Entities
- Quince Therapeutics, Inc. (company) — the registrant filing the 8-K/A
- $0.001 (dollar_amount) — par value per share of Common Stock
- QNCX (company) — trading symbol for Quince Therapeutics' Common Stock
- October 20, 2023 (date) — date of the earliest event reported in the original 8-K
- January 5, 2024 (date) — filing date of the 8-K/A
FAQ
What is the purpose of this 8-K/A filing by Quince Therapeutics, Inc.?
This 8-K/A (Amendment No. 1) serves to amend a previous Current Report on Form 8-K filed by Quince Therapeutics, Inc., specifically to provide updated information regarding its securities registered pursuant to Section 12(b) of the Act.
What specific information about Quince Therapeutics' stock is clarified in this amendment?
The amendment clarifies that the 'Common Stock (par value $0.001 per share)' of Quince Therapeutics, Inc. is registered under the 'Trading Symbol' QNCX and is listed on the Nasdaq Stock Market.
What was the date of the earliest event reported in the original 8-K that this amendment refers to?
The date of the earliest event reported in the original 8-K was October 20, 2023.
What is the par value of Quince Therapeutics, Inc.'s Common Stock as stated in the filing?
The par value of Quince Therapeutics, Inc.'s Common Stock is $0.001 per share.
On which exchange is Quince Therapeutics, Inc.'s Common Stock registered?
Quince Therapeutics, Inc.'s Common Stock (trading symbol QNCX) is registered on the Nasdaq Stock Market.
Filing Stats: 939 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-01-05 16:01:33
Key Financial Figures
- $0.001 — ich registered Common Stock (par value $0.001 per share) QNCX The Nasdaq Stock Ma
Filing Documents
- d109820d8ka.htm (8-K/A) — 31KB
- d109820dex231.htm (EX-23.1) — 2KB
- d109820dex991.htm (EX-99.1) — 349KB
- d109820dex992.htm (EX-99.2) — 295KB
- d109820dex993.htm (EX-99.3) — 177KB
- 0001193125-24-003344.txt ( ) — 1115KB
- qncx-20231020.xsd (EX-101.SCH) — 4KB
- qncx-20231020_def.xml (EX-101.DEF) — 14KB
- qncx-20231020_lab.xml (EX-101.LAB) — 23KB
- qncx-20231020_pre.xml (EX-101.PRE) — 15KB
- d109820d8ka_htm.xml (XML) — 7KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a) Financial Statements of Business Acquired The historical audited consolidated financial statements of EryDel as of and for the years ended December 31, 2022 and 2021, together with the notes related thereto and the Report of Independent Registered Public Accounting Firm thereon, are filed as Exhibit 99.1 to this Amendment No. 1 and incorporated by reference herein. The unaudited condensed consolidated financial statements of EryDel as of and for three and nine months ended September 30, 2023 and 2022, together with the unaudited notes related thereto, are filed as Exhibit 99.2 to this Amendment No. 1 and incorporated by reference herein. (b) Pro Forma Financial Information The unaudited pro forma condensed combined balance sheet as of September 30, 2023 and unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023 and the year ended December 31, 2022, together with the notes related thereto, each giving effect to the Acquisition, are included as Exhibit 99.3 to this Amendment No. 1 and are incorporated herein by reference. (d) Exhibits Exhibit No. Description 23.1 Consent of KPMG S.p.A. 99.1 The audited consolidated financial statements of EryDel as of and for the year ended December 31, 2022 and 2021, including the notes related thereto and the audit report thereon of the independent auditors. 99.2 The unaudited condensed consolidated financial statements of EryDel as of and for each of the three and nine months ended September 30, 2023 and 2022, and the notes related thereto. 99.3 The unaudited pro forma condensed combined balance sheet as of September 30, 2023, and unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023 and year ended December 31, 2022, and the notes related thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUINCE THERAPEUTICS, INC. Date: January 5, 2024 By: /s/ Dirk Thye Dirk Thye Chief Executive Officer